Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non–insulin dependent diabetes mellitus
- 25 October 2000
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 36 (5), 1529-1535
- https://doi.org/10.1016/s0735-1097(00)00895-0
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Increased Intimal Hyperplasia in Patients With Impaired Glucose Tolerance After Coronary Stent Implantation: A Serial Intravascular Ultrasound StudyJournal of the American College of Cardiology, 1998
- Three-year clinical follow-up after Palmaz-Schatz stentingJournal of the American College of Cardiology, 1996
- Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy AloneDiabetic Medicine, 1996
- Potential mechanisms promoting restenosis in diabetic patientsJournal of the American College of Cardiology, 1996
- Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysisJournal of the American College of Cardiology, 1995
- Luminal loss and site of restenosis after Palmaz-Schatz coronary stent implantationThe American Journal of Cardiology, 1995
- Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation.JCI Insight, 1994
- Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: association with overexpression of PDGF β‐receptorsEuropean Journal of Clinical Investigation, 1993
- Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM SubjectsDiabetes Care, 1992
- Insulin and Atheroma: 20-Yr PerspectiveDiabetes Care, 1990